Daphne

Press release - The Daphne Caruana Galizia Prize for Journalism - call for submission of entries

Retrieved on: 
화요일, 5월 28, 2024
Democracy, Legislation, Commission, Daphne, European Parliament, European, Sale, Civil service commission, European Commission, The Prize, Panama Papers, Freedom, Parliament, Prize, Pharmaceutical industry

The Daphne Caruana Galizia Prize for Journalism - call

Key Points: 
  • The Daphne Caruana Galizia Prize for Journalism - call
    for submission of entries
    On 3 May, the World Press Freedom Day, the European Parliament officially launched the call for submissions for entries to the Daphne Caruana Galizia Prize for Journalism.
  • Each year the European Parliament renews its commitment to uphold media and press freedom, in tribute to the fearless journalist Daphne Caruana Galizia.
  • The award ceremony takes place each year around 16 October, the date Daphne Caruana Galizia was assassinated.
  • The prize and the €20 000 prize money demonstrates the European Parliament’s strong support for investigative journalism and the importance of a free press.

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Retrieved on: 
수요일, 5월 22, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Genomics, Patient, Prevalence, DNA, NeXT, Colorectal cancer, Circulating tumor DNA, Ultra, Breast cancer, Neoplasm, MRD, ASCO, CRC, THP, Kinetics, Society, Daphne, Annual general meeting, PSNL, Medical imaging

“As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • The two studies that were selected to appear as podium presentations are:
    Overview: Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
  • Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here .
  • Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
화요일, 5월 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, PRTC, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Multimedia, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Patient, Acquisition, Pleasure, MBA, Growth

View the full release here: https://www.businesswire.com/news/home/20240507753971/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507753971/en/
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments (Graphic: Business Wire)
    The appointments follow the recent launch of Seaport , PureTech’s newest Founded Entity, with a $100 million Series A financing round.
  • Following the Series A financing, PureTech holds equity ownership in Seaport of 61.5 percent on a diluted basis.
  • In addition, Michael Chen, Ph.D., Co-founder, was named Chief Scientific Officer, and Eric Green, MBA, was appointed Chief Operating Officer.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.

Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
화요일, 5월 7, 2024
Health, Pharmaceutical, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Science, Patient, Acquisition, Pleasure, MBA, Growth

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.
  • “We are incredibly honored to welcome Denice to our Board of Directors.
  • She is an exceptional healthcare leader with a track record of successfully guiding organizations through significant growth and transformation,” said Steve Paul, M.D., Founder and Chair of the Board of Directors at Seaport.

NSG BioLabs Fuels Biotech Innovation in Singapore and Southeast Asia Through Partnerships with EnterpriseSG and Merck, Alongside Investments from Celadon Partners and ClavystBio

Retrieved on: 
수요일, 5월 8, 2024
Ecosystem, Incubator, Daphne, Health, Health care, Biosafety, Partnership, Research, Biomedicine, Science, Synthetic biology, Temasek, NSG, Spirit level, Enterprise Singapore, Medicine, Dicarboxylic acid, Growth

Moreover, these milestones underscore NSG BioLabs as an ecosystem catalyst, providing value-add services and networks, which are important in driving scientific innovation and business growth.

Key Points: 
  • Moreover, these milestones underscore NSG BioLabs as an ecosystem catalyst, providing value-add services and networks, which are important in driving scientific innovation and business growth.
  • With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with partners, suppliers and industry experts, NSG BioLabs has helped over 40 companies as residents.
  • To further its mission of supporting biotech innovators, NSG BioLabs also closed a US$14.5 million strategic investment round, led by Celadon Partners with participation from ClavystBio.
  • Now, with three sites totaling 35,000 square feet, NSG BioLabs cements its space as a key hub for biotech innovation.

insitro Hires AI and Machine Learning Visionary, Emily Fox, Ph.D., as Senior Vice President of AI/ML

Retrieved on: 
화요일, 4월 30, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Health Technology, Data Analytics, Software, Artificial Intelligence, Clinical Trials, Stanford University, University, Genetics, Scientist, Genomics, Ecosystem, Computer science, Chan Zuckerberg Biohub, Sloan Research Fellowship, Daphne, Johnson & Johnson, Eli Lilly, Machine learning, Neuroscience, Computational biology, Research, NSF, Amazon, Data science, Department of Statistics, Translation, Sequoia, Data collection, Biology, Methodology, ONR, Apple, Drug development, Drug discovery, Knowledge, Engineering, Seattle Coronavirus Assessment Network, MIT, Medical device

insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning.

Key Points: 
  • insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning.
  • “Her groundbreaking work in machine learning, alongside her track record in translating research into impactful applications in healthcare, aligns perfectly with our mission to revolutionize drug discovery through data-driven approaches.
  • With Emily joining insitro, their combined efforts in leveraging AI for biology discovery and drug development are set to revolutionize the field.
  • It’s collaborations like these that highlight the power of diverse minds in AI, driving not just technological progress, but societal betterment as well.”

Stoic Equity Partners Team Expands Again, Adds Two New Director Roles

Retrieved on: 
목요일, 2월 22, 2024
Marketing, Dunkin, Project management, Intelligence, Auburn University, Chicago Mercantile Exchange, Pet, Daphne, Family, Knowledge, Starbucks, Development, Financial services

DAPHNE, Ala., Feb. 22, 2024 /PRNewswire/ -- Daphne, Ala. based Stoic Equity Partners is proud to welcome its newest team members, Chris McCoy and Frank Pishler. McCoy recently joined the firm as Director of Project Management & Retail Development and Pishler as Director of Investor Relations.

Key Points: 
  • Stoic Welcomes Director of Investor Relations, Frank Pishler and Director of Project Management & Retail Development, Chris McCoy
    DAPHNE, Ala., Feb. 22, 2024 /PRNewswire/ -- Daphne, Ala. based Stoic Equity Partners is proud to welcome its newest team members, Chris McCoy and Frank Pishler.
  • McCoy recently joined the firm as Director of Project Management & Retail Development and Pishler as Director of Investor Relations.
  • McCoy's role at Stoic Equity Partners includes managing the firm's renovations and ground up retail developments.
  • Pishler's role at Stoic Equity Partners includes providing investors with the intelligence and critical information needed to aid them in placing and managing their capital with us.

PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
수요일, 1월 3, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, PRTC, Daphne, PST, EST, Conference, Patient

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.
  • A webcast of the presentation will be available at https://investors.puretechhealth.com .

Common Sense Privacy Launches New AI-Powered Software Platform to Help Companies Manage Data Privacy Regulations

Retrieved on: 
수요일, 12월 13, 2023
Data Management, Technology, Professional Services, Business, Online Privacy, Security, Apps, Applications, Software, Artificial Intelligence, Legal, Internet, LLM Communications, Daphne, Privacy, GDPR, Risk, European, Left–right political spectrum, Common Sense, Child, Dashboard, Common Sense Media, Common, AI, Medical device, Cryptocurrency, Online shopping, Customer service

Common Sense Privacy , a business-focused software platform augmented with state-of-the-art AI, debuts software to help companies better assess and manage privacy regulatory risks.

Key Points: 
  • Common Sense Privacy , a business-focused software platform augmented with state-of-the-art AI, debuts software to help companies better assess and manage privacy regulatory risks.
  • “We’re proud to offer companies a simple, cost-effective way to understand their privacy choices and manage risk,” said Daphne Li , CEO of Common Sense Privacy.
  • Common Sense Privacy helps companies protect consumer privacy and facilitates responsible safeguards.”
    There are an estimated 5,000 new apps every day that need privacy labels for app store listing, and an estimated 252,000 new websites every day that must comply with consumer privacy regulations.
  • “After evaluating thousands of companies’ privacy policies, we see the challenges that companies face in meeting privacy best practice standards,” said Ellen Pack, President of Common Sense Media.

WorldQuant University Announces John Endrud as Chief Executive Officer

Retrieved on: 
목요일, 11월 30, 2023
Other Professional Services, Data Analytics, Other Education, Continuing, Professional Services, University, Education, Training, WorldQuant, Research, Daphne, Executive, Distance education, Workforce, Student, DEAC, Distance Education Accrediting Commission, WorldQuant University, Growth, Management, Nursing

WorldQuant University (WQU), which offers entirely free global education in data sciences, today announced that it has appointed John Endrud as Chief Executive Officer, beginning in December 2023.

Key Points: 
  • WorldQuant University (WQU), which offers entirely free global education in data sciences, today announced that it has appointed John Endrud as Chief Executive Officer, beginning in December 2023.
  • Endrud has more than 25 years of experience at the intersection of technology and higher education, partnering with colleges, universities, and employers to achieve organizational growth and develop market-leading innovations.
  • Most recently, Endrud served as the Executive Vice President and Chief Development Officer at Collegis Education, a leading provider of managed technology and enrollment growth services for colleges and universities.
  • Since its establishment in 2015, WorldQuant University has made remarkable strides towards its mission to make advanced, quality education and advanced degrees accessible to capable students everywhere through cost-free online courses.